Tyr185
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus®
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Tyr185  -  JNK1 (human)

Site Information
tsFMMtPyVVtRYYR   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 447645
Available spectra:  1 CST
Associated spectra:  2 CST

In vivo Characterization
Methods used to characterize site in vivo:
[32P] bio-synthetic labeling ( 1147 ) , electrophoretic mobility shift ( 1118 , 1125 ) , immunoprecipitation ( 49 , 286 , 293 , 336 , 464 , 756 , 1146 ) , mass spectrometry ( 6 , 9 , 22 , 24 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 39 , 40 , 41 , 42 , 44 , 45 , 46 , 47 , 48 , 51 , 52 , 53 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , 67 , 68 , 69 , 70 , 71 , 72 , 73 , 74 , 76 , 77 , 78 , 79 , 80 , 81 , 82 , 83 , 84 , 85 , 86 , 87 , 88 , 89 , 90 , 91 , 92 , 93 , 94 , 95 , 96 , 97 , 98 , 99 , 100 , 101 , 102 , 103 , 105 , 106 , 107 , 108 , 109 , 110 , 111 , 114 , 115 , 116 , 117 , 118 , 119 , 120 , 121 , 122 , 123 , 124 , 125 , 126 , 129 , 130 , 131 , 132 , 133 , 134 , 135 , 136 , 137 , 138 , 139 , 140 , 141 , 142 , 143 , 144 , 145 , 146 , 147 , 148 , 149 , 150 , 151 , 152 , 153 , 154 , 155 , 156 , 157 , 158 , 159 , 160 , 161 , 162 , 163 , 164 , 165 , 166 , 167 , 168 , 169 , 170 , 172 , 173 , 174 , 176 , 179 , 180 , 181 , 182 , 183 , 184 , 185 , 186 , 187 , 188 , 189 , 191 , 192 , 193 , 194 , 195 , 196 , 197 , 198 , 199 , 200 , 201 , 202 , 203 , 204 , 205 , 206 , 207 , 208 , 209 , 210 , 211 , 212 , 213 , 214 , 215 , 217 , 218 , 219 , 220 , 221 , 222 , 223 , 224 , 225 , 226 , 227 , 228 , 229 , 230 , 231 , 232 , 233 , 234 , 235 , 236 , 237 , 238 , 239 , 240 , 241 , 242 , 243 , 244 , 245 , 246 , 247 , 248 , 249 , 250 , 251 , 252 , 253 , 254 , 255 , 256 , 257 , 258 , 259 , 260 , 261 , 262 , 263 , 264 , 265 , 266 , 267 , 268 , 269 , 270 , 271 , 272 , 273 , 274 , 275 , 276 , 277 , 278 , 279 , 280 , 281 , 282 , 283 , 288 , 289 , 292 , 294 , 295 , 296 , 297 , 298 , 299 , 300 , 301 , 302 , 303 , 304 , 305 , 306 , 307 , 308 , 309 , 312 , 313 , 314 , 315 , 316 , 317 , 318 , 319 , 320 , 321 , 322 , 323 , 324 , 326 , 327 , 329 , 330 , 331 , 332 , 333 , 337 , 338 , 339 , 340 , 341 , 342 , 343 , 344 , 345 , 346 , 347 , 348 , 349 , 350 , 351 , 352 , 353 , 354 , 355 , 356 , 357 , 358 , 359 , 360 , 361 , 362 , 363 , 364 , 365 , 366 , 367 , 368 , 369 , 370 , 371 , 372 , 373 , 374 , 375 , 376 , 377 , 378 , 379 , 380 , 381 , 382 , 383 , 384 , 385 , 386 , 387 , 388 , 389 , 390 , 391 , 392 , 393 , 394 , 395 , 396 , 397 , 398 , 399 , 400 , 401 , 402 , 404 , 405 , 406 , 407 , 408 , 409 , 410 , 411 , 412 , 413 , 414 , 415 , 416 , 417 , 418 , 419 , 421 , 422 , 423 , 424 , 425 , 426 , 428 , 429 , 430 , 431 , 432 , 433 , 434 , 435 , 436 , 437 , 438 , 439 , 440 , 441 , 442 , 443 , 444 , 445 , 446 , 447 , 448 , 449 , 450 , 451 , 452 , 453 , 454 , 455 , 456 , 457 , 458 , 459 , 460 , 461 , 462 , 463 , 465 , 466 , 467 , 468 , 469 , 470 , 471 , 472 , 473 , 474 , 475 , 476 , 477 , 478 , 479 , 480 , 481 , 482 , 483 , 484 , 485 , 486 , 487 , 488 , 489 , 490 , 491 , 492 , 493 , 494 , 495 , 496 , 497 , 498 , 499 , 500 , 501 , 502 , 503 , 504 , 505 , 506 , 507 , 508 , 509 , 511 , 512 , 513 , 514 , 515 , 516 , 517 , 518 , 519 , 520 , 522 , 523 , 524 , 525 , 526 , 527 , 528 , 529 , 530 , 531 , 532 , 533 , 534 , 535 , 536 , 537 , 538 , 539 , 540 , 541 , 542 , 543 , 544 , 545 , 546 , 547 , 548 , 549 , 550 , 551 , 552 , 553 , 554 , 555 , 556 , 557 , 558 , 559 , 560 , 561 , 562 , 563 , 564 , 565 , 566 , 567 , 568 , 570 , 571 , 572 , 573 , 574 , 575 , 576 , 577 , 578 , 579 , 580 , 581 , 582 , 583 , 584 , 585 , 586 , 587 , 588 , 589 , 590 , 591 , 592 , 593 , 594 , 595 , 596 , 597 , 598 , 599 , 600 , 601 , 602 , 603 , 604 , 605 , 606 , 607 , 608 , 609 , 610 , 611 , 612 , 613 , 614 , 615 , 616 , 617 , 618 , 619 , 620 , 621 , 622 , 623 , 624 , 625 , 626 , 627 , 628 , 629 , 630 , 631 , 632 , 633 , 634 , 635 , 636 , 637 , 638 , 639 , 640 , 641 , 642 , 643 , 644 , 645 , 646 , 647 , 648 , 649 , 650 , 651 , 652 , 653 , 654 , 655 , 656 , 657 , 658 , 659 , 660 , 661 , 662 , 663 , 664 , 665 , 666 , 667 , 668 , 669 , 670 , 671 , 672 , 673 , 674 , 675 , 676 , 677 , 678 , 679 , 680 , 681 , 682 , 683 , 684 , 685 , 687 , 688 , 689 , 690 , 691 , 692 , 693 , 694 , 695 , 696 , 697 , 698 , 699 , 700 , 701 , 702 , 703 , 704 , 705 , 706 , 707 , 708 , 709 , 710 , 711 , 712 , 713 , 714 , 715 , 716 , 717 , 718 , 719 , 720 , 721 , 722 , 723 , 724 , 725 , 726 , 727 , 728 , 729 , 730 , 731 , 732 , 733 , 734 , 735 , 736 , 737 , 738 , 739 , 740 , 741 , 742 , 743 , 744 , 745 , 746 , 747 , 748 , 750 , 751 , 752 , 755 , 757 , 759 , 760 , 761 , 762 , 763 , 764 , 765 , 766 , 767 , 768 , 769 , 770 , 771 , 772 , 775 , 776 , 777 , 778 , 779 , 780 , 781 , 782 , 783 , 784 , 785 , 786 , 787 , 788 , 789 , 790 , 791 , 792 , 793 , 794 , 796 , 797 , 798 , 799 , 800 , 801 , 802 , 803 , 804 , 805 , 806 , 807 , 808 , 809 , 810 , 811 , 812 , 813 , 814 , 815 , 816 , 817 , 818 , 819 , 820 , 821 , 822 , 823 , 824 , 825 , 826 , 827 , 828 , 829 , 830 , 831 , 832 , 833 , 835 , 836 , 837 , 838 , 839 , 840 , 841 , 842 , 843 , 844 , 845 , 846 , 847 , 849 , 850 , 851 , 852 , 853 , 854 , 855 , 856 , 857 , 858 , 859 , 860 , 861 , 862 , 863 , 865 , 866 , 867 , 868 , 869 , 870 , 871 , 872 , 873 , 874 , 875 , 876 , 877 , 878 , 879 , 880 , 881 , 882 , 883 , 884 , 885 , 886 , 887 , 888 , 890 , 891 , 892 , 893 , 894 , 895 , 896 , 901 , 902 , 903 , 904 , 905 , 906 , 907 , 908 , 909 , 910 , 911 , 912 , 913 , 914 , 916 , 917 , 918 , 919 , 920 , 921 , 922 , 923 , 925 , 926 , 927 , 929 , 930 , 931 , 932 , 933 , 934 , 935 , 936 , 937 , 940 , 941 , 942 , 943 , 944 , 945 , 946 , 948 , 953 , 954 , 955 , 956 , 957 , 959 , 960 , 961 , 965 , 966 , 967 , 968 , 969 , 970 , 971 , 972 , 973 , 974 , 975 , 976 , 977 , 978 , 979 , 980 , 981 , 983 , 984 , 985 , 986 , 987 , 988 , 989 , 990 , 991 , 992 , 993 , 994 , 995 , 996 , 997 , 998 , 999 , 1000 , 1001 , 1002 , 1003 , 1004 , 1005 , 1006 , 1007 , 1008 , 1009 , 1010 , 1011 , 1012 , 1013 , 1014 , 1015 , 1016 , 1017 , 1020 , 1021 , 1025 , 1026 , 1028 , 1029 , 1030 , 1031 , 1032 , 1033 , 1034 , 1035 , 1036 , 1038 , 1039 , 1040 , 1041 , 1042 , 1043 , 1044 , 1045 , 1046 , 1047 , 1048 , 1049 , 1050 , 1051 , 1052 , 1053 , 1054 , 1055 , 1058 , 1059 , 1060 , 1061 , 1062 , 1063 , 1064 , 1066 , 1067 , 1068 , 1069 , 1070 , 1071 , 1072 , 1073 , 1074 , 1075 , 1076 , 1078 , 1079 , 1080 , 1081 , 1082 , 1083 , 1084 , 1085 , 1087 , 1090 , 1091 , 1092 , 1093 , 1094 , 1095 , 1096 , 1099 , 1100 , 1101 , 1102 , 1104 , 1105 , 1106 , 1107 , 1113 , 1114 , 1115 , 1116 , 1122 , 1123 , 1124 ) , microscopy-colocalization with upstream kinase ( 773 , 924 , 1121 ) , mutation of modification site ( 3 , 962 , 1089 , 1098 , 1147 , 1149 ) , peptide sequencing ( 403 , 1110 ) , phospho-antibody ( 1 , 2 , 3 , 4 , 5 , 7 , 8 , 10 , 11 , 12 , 13 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 25 , 27 , 38 , 49 , 104 , 113 , 127 , 178 , 190 , 284 , 285 , 286 , 287 , 293 , 310 , 311 , 328 , 334 , 335 , 336 , 420 , 427 , 464 , 510 , 521 , 569 , 749 , 753 , 756 , 758 , 773 , 774 , 795 , 834 , 848 , 889 , 897 , 898 , 899 , 915 , 924 , 928 , 938 , 939 , 947 , 949 , 951 , 952 , 958 , 962 , 963 , 964 , 982 , 1018 , 1019 , 1022 , 1023 , 1024 , 1027 , 1056 , 1057 , 1065 , 1077 , 1086 , 1089 , 1097 , 1098 , 1103 , 1108 , 1109 , 1111 , 1112 , 1117 , 1118 , 1119 , 1120 , 1125 , 1126 , 1127 , 1128 , 1129 , 1130 , 1132 , 1134 , 1135 , 1136 , 1137 , 1138 , 1139 , 1140 , 1141 , 1142 , 1143 , 1144 , 1146 ) , phosphoamino acid analysis ( 754 ) , phosphopeptide mapping ( 1149 ) , western blotting ( 1 , 2 , 3 , 4 , 5 , 7 , 8 , 10 , 11 , 12 , 13 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 25 , 27 , 38 , 49 , 104 , 113 , 127 , 178 , 190 , 284 , 286 , 287 , 293 , 310 , 311 , 328 , 334 , 335 , 336 , 403 , 420 , 427 , 464 , 510 , 521 , 569 , 749 , 753 , 754 , 756 , 758 , 773 , 774 , 795 , 834 , 848 , 889 , 897 , 898 , 899 , 915 , 924 , 928 , 939 , 947 , 949 , 951 , 952 , 958 , 962 , 963 , 964 , 982 , 1018 , 1019 , 1022 , 1023 , 1024 , 1027 , 1056 , 1057 , 1065 , 1077 , 1086 , 1097 , 1098 , 1110 , 1111 , 1112 , 1117 , 1119 , 1120 , 1126 , 1127 , 1129 , 1130 , 1134 , 1137 , 1138 , 1140 , 1142 , 1143 , 1146 , 1149 )
Disease tissue studied:
atrial fibrillation ( 863 , 873 , 880 ) , adenoid cystic carcinoma ( 762 , 764 ) , bile-duct cancer ( 729 , 731 ) , bladder cancer ( 969 , 970 , 971 ) , bladder cancer, surrounding tissue ( 498 , 499 , 500 ) , bone cancer ( 51 , 510 , 754 , 899 , 901 , 925 , 926 , 951 , 1142 ) , Ewing's sarcoma ( 51 , 925 ) , osteosarcoma ( 901 , 926 ) , brain cancer ( 22 , 180 , 181 , 189 , 245 , 328 , 462 , 463 , 799 , 812 , 813 , 814 , 887 , 888 , 958 , 976 , 1003 , 1020 , 1021 , 1047 , 1051 , 1053 , 1054 , 1062 , 1063 , 1072 , 1075 ) , astrocytoma ( 180 , 181 , 189 , 1003 ) , glioblastoma ( 22 , 245 , 328 , 462 , 463 , 958 , 976 , 1020 , 1021 , 1053 , 1062 , 1063 , 1072 , 1075 ) , glioblastoma multiforme ( 799 , 812 , 813 , 814 , 887 , 888 , 1020 , 1021 , 1063 , 1072 , 1075 ) , glioma ( 22 , 245 , 328 , 462 , 463 , 799 , 812 , 813 , 814 , 887 , 888 , 958 , 976 , 1020 , 1021 , 1053 , 1062 , 1063 , 1072 , 1075 ) , breast cancer ( 24 , 48 , 311 , 313 , 336 , 403 , 495 , 496 , 497 , 521 , 585 , 586 , 774 , 855 , 856 , 857 , 858 , 859 , 860 , 861 , 865 , 866 , 867 , 875 , 895 , 927 , 929 , 967 , 979 , 980 , 981 , 986 , 987 , 992 , 993 , 994 , 995 , 1037 , 1061 , 1066 , 1134 ) , breast ductal carcinoma ( 24 , 1061 , 1066 ) , HER2 positive breast cancer ( 6 ) , luminal A breast cancer ( 6 ) , luminal B breast cancer ( 6 ) , breast cancer, surrounding tissue ( 496 ) , breast cancer, triple negative ( 6 , 24 , 979 , 980 , 981 , 1066 ) , colorectal cancer ( 96 , 97 , 98 , 176 , 187 , 188 , 335 , 349 , 683 , 685 , 687 , 711 , 712 , 714 , 852 , 1015 , 1016 , 1017 , 1027 , 1032 , 1033 , 1034 , 1035 , 1111 , 1134 ) , colorectal carcinoma ( 96 , 97 , 98 , 187 , 188 , 335 , 349 , 1015 , 1016 , 1017 , 1027 , 1032 , 1033 , 1034 , 1035 , 1111 , 1134 ) , colorectal cancer, surrounding tissue ( 294 , 312 , 347 , 348 , 678 , 679 , 680 , 682 , 684 , 850 , 851 ) , esophageal cancer ( 84 , 85 , 372 , 375 , 376 , 377 , 378 , 379 , 380 , 579 , 580 , 583 , 593 , 596 , 597 , 605 , 608 , 609 , 612 , 613 , 614 , 616 , 617 , 619 , 623 , 627 , 630 , 632 , 635 , 636 , 637 , 640 , 641 , 643 , 645 , 646 , 648 , 651 , 655 , 656 , 657 , 662 , 663 , 664 , 666 , 667 , 670 , 671 , 1039 , 1040 ) , esophageal carcinoma ( 372 , 375 , 376 , 377 , 378 , 379 ) , esophageal cancer, surrounding tissue ( 592 , 594 , 595 , 598 , 599 , 600 , 601 , 602 , 603 , 604 , 606 , 607 , 610 , 611 , 615 , 618 , 620 , 621 , 622 , 624 , 625 , 626 , 628 , 629 , 631 , 633 , 634 , 638 , 639 , 642 , 644 , 647 , 649 , 653 , 658 , 659 , 660 , 661 , 665 , 668 , 669 , 672 , 673 ) , liposarcoma ( 51 ) , gastric cancer ( 46 , 58 , 64 , 65 , 66 , 67 , 68 , 69 , 70 , 71 , 72 , 73 , 74 , 123 , 124 , 125 , 170 , 305 , 343 , 373 , 466 , 468 , 470 , 472 , 473 , 474 , 475 , 476 , 481 , 482 , 484 , 485 , 486 , 775 , 777 , 779 , 781 , 784 , 785 , 787 , 789 , 868 , 870 , 871 , 879 , 881 , 884 , 885 , 886 , 894 , 896 ) , gastric carcinoma ( 58 , 64 , 65 , 66 , 67 , 68 , 69 , 70 , 71 , 72 , 123 , 124 , 125 , 170 , 305 , 343 , 373 , 775 , 777 , 779 , 781 , 868 , 870 , 871 , 881 , 884 , 886 , 896 ) , gastric carcinoma, surrounding tissue ( 467 , 469 , 471 , 477 , 478 , 479 , 480 , 483 , 487 , 776 , 778 , 780 , 783 , 786 , 790 , 791 , 792 , 869 , 876 , 877 , 878 ) , kidney cancer ( 503 , 515 , 519 , 968 ) , kidney cancer, surrounding tissue ( 518 , 520 ) , laryngeal cancer ( 854 ) , leukemia ( 7 , 99 , 100 , 101 , 178 , 277 , 278 , 279 , 280 , 281 , 282 , 283 , 331 , 332 , 395 , 399 , 402 , 410 , 421 , 422 , 423 , 424 , 426 , 428 , 429 , 430 , 431 , 432 , 441 , 442 , 443 , 461 , 872 , 921 , 922 , 923 , 930 , 931 , 932 , 933 , 934 , 964 , 997 , 998 , 999 , 1002 , 1014 , 1031 , 1036 , 1038 , 1074 , 1102 , 1104 , 1105 ) , acute lymphocytic leukemia ( 292 , 999 ) , acute myelogenous leukemia ( 7 , 292 , 930 , 931 , 932 , 933 , 934 , 997 , 998 , 1002 , 1014 , 1031 , 1036 , 1038 , 1102 , 1104 , 1105 ) , chronic lymphocytic leukemia ( 1074 ) , chronic myelogenous leukemia ( 99 , 100 , 101 , 277 , 278 , 279 , 280 , 281 , 282 , 283 , 331 , 332 , 395 , 399 , 402 , 410 , 421 , 422 , 423 , 424 , 426 , 428 , 429 , 430 , 431 , 432 , 441 , 442 , 443 , 461 , 872 ) , T cell leukemia ( 178 , 964 ) , liver cancer ( 285 , 288 , 353 , 354 , 355 , 356 , 357 , 358 , 359 , 360 , 361 , 362 , 364 , 365 , 366 , 367 , 403 , 502 , 505 , 506 , 522 , 524 , 527 , 534 , 535 , 536 , 539 , 543 , 547 , 550 , 552 , 561 , 562 , 567 , 572 , 574 , 676 , 677 , 690 , 691 , 694 , 696 , 700 , 701 , 702 , 710 , 728 , 730 , 750 , 751 , 752 , 796 , 797 , 798 , 832 , 841 , 842 , 845 , 889 , 893 , 1057 , 1142 ) , liver adenocarcinoma ( 677 ) , cholangiocellular carcinoma ( 288 , 562 , 694 , 710 , 796 , 893 ) , cholangiocellular carcinoma, surrounding tissue ( 533 , 545 , 699 , 708 ) , hepatocellular carcinoma ( 522 , 524 , 527 , 534 , 535 , 536 , 539 , 543 , 547 , 550 , 552 , 561 , 567 , 572 , 574 , 691 , 696 , 700 , 702 , 797 , 832 , 841 , 842 , 845 ) , hepatocellular carcinoma, surrounding tissue ( 523 , 525 , 526 , 528 , 537 , 538 , 540 , 541 , 542 , 546 , 548 , 549 , 551 , 553 , 554 , 555 , 556 , 557 , 559 , 560 , 564 , 566 , 568 , 692 , 693 , 695 , 697 , 698 , 709 , 831 , 833 , 838 , 839 , 843 , 846 , 847 , 892 ) , liver cancer, surrounding tissue ( 352 , 363 , 501 , 504 , 558 , 563 ) , lung cancer ( 1 , 2 , 8 , 27 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 41 , 59 , 60 , 61 , 62 , 63 , 82 , 95 , 104 , 127 , 179 , 182 , 183 , 184 , 185 , 186 , 194 , 195 , 196 , 197 , 198 , 199 , 200 , 201 , 202 , 203 , 204 , 205 , 206 , 207 , 208 , 210 , 240 , 243 , 286 , 329 , 370 , 383 , 384 , 386 , 387 , 388 , 390 , 391 , 392 , 393 , 394 , 396 , 397 , 398 , 400 , 403 , 405 , 408 , 420 , 427 , 444 , 445 , 446 , 448 , 449 , 450 , 454 , 456 , 457 , 459 , 575 , 576 , 577 , 578 , 581 , 582 , 681 , 715 , 716 , 717 , 718 , 719 , 720 , 721 , 755 , 758 , 759 , 760 , 793 , 794 , 849 , 896 , 897 , 940 , 941 , 942 , 943 , 944 , 945 , 946 , 953 , 954 , 955 , 956 , 957 , 959 , 960 , 961 , 965 , 966 , 972 , 988 , 996 , 1006 , 1009 , 1010 , 1011 , 1012 , 1013 , 1023 , 1029 , 1030 , 1041 , 1042 , 1044 , 1048 , 1050 , 1052 , 1055 , 1058 , 1060 , 1064 , 1067 , 1070 , 1076 , 1078 , 1079 , 1083 , 1084 , 1085 , 1087 , 1090 , 1091 , 1092 , 1093 , 1094 , 1095 , 1096 , 1099 , 1101 , 1106 , 1116 , 1118 , 1123 , 1134 , 1143 ) , non-small cell lung cancer ( 1 , 2 , 8 , 27 , 31 , 32 , 33 , 35 , 36 , 37 , 40 , 45 , 47 , 59 , 60 , 61 , 62 , 63 , 82 , 95 , 179 , 182 , 183 , 184 , 185 , 186 , 194 , 195 , 196 , 198 , 199 , 200 , 201 , 202 , 203 , 204 , 205 , 206 , 207 , 208 , 210 , 286 , 329 , 403 , 405 , 427 , 444 , 445 , 446 , 448 , 449 , 450 , 454 , 456 , 457 , 459 , 681 , 715 , 716 , 717 , 718 , 759 , 760 , 793 , 849 , 896 , 897 , 940 , 941 , 945 , 946 , 953 , 954 , 955 , 956 , 957 , 959 , 961 , 988 , 996 , 1009 , 1010 , 1011 , 1012 , 1013 , 1029 , 1030 , 1041 , 1042 , 1044 , 1048 , 1058 , 1060 , 1067 , 1070 , 1078 , 1079 , 1083 , 1084 , 1085 , 1087 , 1090 , 1092 , 1093 , 1094 , 1095 , 1096 , 1101 , 1106 , 1116 , 1123 ) , non-small cell lung cancer, surrounding tissue ( 406 , 788 ) , non-small cell lung adenocarcinoma ( 2 , 8 , 27 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 40 , 41 , 82 , 95 , 184 , 185 , 186 , 194 , 195 , 196 , 198 , 199 , 200 , 201 , 202 , 203 , 204 , 205 , 206 , 207 , 208 , 210 , 286 , 329 , 370 , 444 , 445 , 446 , 448 , 449 , 450 , 454 , 456 , 457 , 459 , 715 , 716 , 717 , 718 , 760 , 793 , 849 , 896 , 945 , 946 , 972 , 1085 , 1090 , 1095 ) , non-small cell lung adenocarcinoma, surrounding tissue ( 209 , 447 , 451 , 452 , 453 , 455 , 458 , 460 ) , non-small cell large cell lung carcinoma ( 32 , 35 ) , non-small cell squamous cell lung carcinoma ( 1 , 34 , 47 , 82 , 197 , 575 , 576 , 577 , 578 , 581 , 582 , 719 , 720 , 721 , 794 ) , small-cell lung cancer ( 29 , 30 , 1099 ) , lung cancer, surrounding tissue ( 238 , 239 , 241 , 242 , 350 , 351 , 385 , 389 ) , lymphoma ( 371 , 964 , 985 , 1024 , 1025 , 1045 , 1046 , 1068 , 1120 ) , anaplastic large cell lymphoma ( 964 , 1068 ) , B cell lymphoma ( 1045 , 1046 ) , Burkitt's lymphoma ( 1120 ) , Hodgkin's lymphoma ( 371 , 985 , 1025 ) , T cell lymphoma ( 1024 ) , neuroblastoma ( 9 , 20 , 300 , 301 , 303 , 304 , 326 , 327 , 807 , 808 , 809 , 810 , 882 , 883 , 902 , 903 , 904 , 905 , 915 , 977 , 978 , 983 , 989 , 990 , 1004 , 1005 , 1047 , 1051 , 1054 ) , oropharyngeal cancer ( 758 ) , squamous cell carcinoma of the oropharynx ( 758 ) , ovarian cancer ( 2 , 246 , 295 , 296 , 297 , 298 , 299 , 314 , 315 , 316 , 317 , 318 , 319 , 320 , 321 , 322 , 324 , 381 , 382 , 407 , 409 , 411 , 412 , 413 , 414 , 415 , 416 , 417 , 418 , 419 , 907 , 908 , 910 , 911 , 912 , 913 , 914 , 1026 ) , ovarian epithelial carcinoma ( 246 , 295 , 297 , 324 ) , pancreatic cancer ( 5 , 336 , 1122 ) , pancreatic carcinoma ( 5 , 336 ) , pancreatic cancer, surrounding tissue ( 584 , 874 ) , multiple myeloma ( 1007 , 1008 , 1043 , 1049 ) , prostate cancer ( 2 , 5 , 310 , 403 , 753 , 1057 ) , salivary gland cancer ( 732 , 733 , 734 , 735 , 736 , 737 , 738 , 739 , 740 , 741 , 742 , 743 ) , melanoma skin cancer ( 16 , 434 , 435 , 436 , 437 , 438 , 439 , 440 , 713 , 724 , 725 , 726 , 727 , 747 , 817 , 818 , 819 , 947 , 1027 , 1056 ) , leiomyosarcoma ( 51 ) , thymic carcinoma ( 217 , 218 , 219 , 220 ) , thyroid cancer ( 829 , 862 , 890 ) , ventricular tachycardia ( 221 , 222 , 223 , 224 , 225 , 226 , 227 , 228 , 229 , 230 , 231 , 232 , 233 , 247 , 248 , 249 , 250 , 251 , 252 , 253 , 254 , 255 , 256 , 257 , 258 , 259 , 260 , 261 , 262 , 263 , 264 , 265 , 266 , 267 , 268 , 269 , 270 , 271 , 272 , 273 , 274 , 275 , 276 ) , diabetes mellitus ( 898 ) , type 2 diabetes ( 898 )
Relevant cell line - cell type - tissue:
'brain, caudate-putamen' ( 915 ) , 'fat, white' ( 51 ) , 'liver, para-cholangiocellular carcinoma tissue' ( 288 ) , 'muscle, skeletal' ( 834 , 898 ) , 143.98.2 (bone cell) ( 926 ) , 184A1 (epithelial) ( 565 ) , 21T (breast cell) ( 336 ) , 23132/87 (gastric) ( 74 ) , 23132/87 (gastric) [RAIG1 (human), knockdown] ( 73 ) , 293 (epithelial) ( 190 , 293 , 544 , 569 , 754 , 756 , 889 , 899 , 915 , 947 , 952 , 962 , 1019 , 1097 , 1130 ) , 293 (epithelial) [FGFR1 (human), transfection] ( 544 ) , 293 (epithelial) [IL-1RA (human)] ( 1022 ) , 293T (epithelial) ( 2 , 38 , 335 , 336 , 774 , 1113 , 1114 ) , 3T3 (fibroblast) ( 1146 ) , 3T3 (fibroblast) [SHP-2 (mouse), homozygous knockout] ( 1125 ) , 639L (renal) ( 968 ) , 703167 (pulmonary) ( 384 ) , A172 (glial) ( 958 ) , A375 (melanocyte) ( 16 , 1027 ) , A431 (epithelial) ( 464 ) , A549 (pulmonary) ( 2 , 8 , 27 , 31 , 41 , 45 , 95 , 104 , 370 , 420 , 758 , 897 , 942 , 943 , 944 , 1023 , 1118 , 1134 , 1143 ) , A549 (pulmonary) [LKB1 (human), no information] ( 849 ) , A673 (muscle cell) ( 51 ) , ACC-S (adenoidal) ( 761 , 763 ) , adipose tissue ( 939 ) , AG1523 (fibroblast) ( 1018 ) , artery ( 1077 ) , AT5BIVA (fibroblast) ( 1144 ) , AZ-521 (gastric) ( 885 ) , B lymphocyte-spleen ( 1127 ) , B lymphoid-blood ( 1074 ) , B16 (melanocyte) ( 947 ) , BACC (adrenal) ( 1129 ) , BAEC (endothelial) ( 19 , 1019 , 1098 , 1103 ) , BEAS-2B (epithelial) ( 703 , 1139 ) , BEAS-2B (epithelial) [LKB1 (human), no information] ( 704 , 705 ) , BHK (fibroblast) [HRas (human)] ( 938 ) , BHK (fibroblast) [KRas (human)] ( 938 ) , BHK (fibroblast) [Sin1 (human)] ( 938 ) , BJAB (B lymphocyte) ( 1120 ) , bladder ( 498 , 499 , 500 ) , bone marrow ( 292 , 930 , 931 , 932 , 933 , 934 ) , brain ( 1020 , 1021 ) , breast ( 6 , 24 , 313 , 495 , 496 , 497 , 855 , 856 , 857 , 858 , 859 , 860 , 861 , 865 , 866 , 867 , 875 , 895 , 927 , 929 , 986 , 987 , 992 , 993 , 994 , 995 ) , BT-20 (breast cell) ( 403 ) , BT-474 (breast cell) ( 585 ) , BT-549 (breast cell) ( 48 ) , BxPC-3 (pancreatic) ( 5 ) , Caco-2 (intestinal) ( 1027 ) , CAD (neuron) ( 924 ) , Caki-2 (renal) ( 991 ) , Cal-12T (pulmonary) ( 37 ) , CAL-29 (bladder cell) ( 971 ) , Calu-3 (pulmonary) ( 33 ) , cardiac-heart ( 248 , 254 , 255 , 259 , 261 , 265 , 267 , 275 ) , CAS-1 (glial) ( 976 ) , CEM (T lymphocyte) ( 964 ) , CEM-C1-15 ( 420 ) , CEM-C7-14 ( 420 ) , cholangiocyte-liver ( 562 , 694 , 710 , 893 ) , CHP126 (neural crest) ( 9 , 989 ) , CHP212 (neural crest) ( 9 , 1047 ) , CHRF (megakaryocyte) ( 1002 ) , CMK (megakaryoblast) ( 1036 , 1105 ) , COLO-680N (esophageal) ( 85 , 380 ) , COLO-680N (esophageal) [RAIG1 (human), knockdown] ( 84 ) , colon ( 294 , 312 , 347 , 348 , 349 , 678 , 679 , 680 , 682 , 683 , 684 , 685 , 687 , 711 , 712 , 714 , 850 , 851 , 852 ) , COS (fibroblast) ( 1098 , 1135 , 1146 , 1149 ) , CV1 (fibroblast) ( 982 ) , DBTRG-05MG (glial) ( 1072 ) , Detroit562 (squamous) ( 758 ) , DLD1 (intestinal) ( 176 ) , DMS153 (pulmonary) ( 36 , 1059 ) , DMS53 (pulmonary) ( 30 ) , DMS79 (pulmonary) ( 29 , 1099 ) , DU 145 (prostate cell) ( 5 , 1089 ) , DV-90 (pulmonary) ( 1006 ) , EFM-19 (breast cell) ( 1000 ) , esophagus ( 579 , 580 , 583 , 592 , 593 , 594 , 595 , 596 , 597 , 598 , 599 , 600 , 601 , 602 , 603 , 604 , 605 , 606 , 607 , 608 , 609 , 610 , 611 , 612 , 613 , 614 , 615 , 616 , 617 , 618 , 619 , 620 , 621 , 622 , 623 , 624 , 625 , 626 , 627 , 628 , 629 , 630 , 631 , 632 , 633 , 634 , 635 , 636 , 637 , 638 , 639 , 640 , 641 , 642 , 643 , 644 , 645 , 646 , 647 , 648 , 649 , 651 , 653 , 655 , 656 , 657 , 658 , 659 , 660 , 661 , 662 , 663 , 664 , 665 , 666 , 667 , 668 , 669 , 670 , 671 , 672 , 673 ) , fibroblast-foreskin [HRas (human)] ( 1141 ) , fibroblast-skin ( 25 ) , FU-OV-1 (ovarian) ( 1026 ) , GI-CA-N (neural crest) ( 9 , 977 ) , GI-LI-N (neuron) ( 9 , 983 ) , glial-brain ( 22 ) , GP293 (fibroblast) ( 284 ) , H4IIe (hepatic) ( 889 ) , HaCaT (keratinocyte) ( 899 , 952 ) , HBMEC (endothelial) ( 19 ) , HCC1143 (breast cell) ( 1066 ) , HCC1395 (breast cell) ( 1061 ) , HCC15 (pulmonary) ( 34 ) , HCC1599 (breast cell) ( 967 ) , HCC366 (pulmonary) ( 1101 ) , HCC38 (breast cell) ( 979 , 980 ) , HCC4006 (pulmonary) ( 2 ) , HCC44 (pulmonary) ( 37 , 1096 ) , HCC70 (breast cell) ( 981 ) , HCC78 (pulmonary) ( 35 , 185 , 186 ) , HCC827 (pulmonary) ( 33 , 286 , 329 , 896 , 945 , 946 , 1085 ) , HCT116 (intestinal) ( 96 , 97 , 98 , 187 , 188 , 335 , 571 , 1017 , 1111 , 1134 ) , HCT15 (intestinal) ( 1032 , 1033 ) , HCT8 (intestinal) ( 1034 , 1035 ) , heart ( 221 , 222 , 223 , 224 , 225 , 226 , 227 , 228 , 229 , 230 , 231 , 232 , 233 , 247 , 249 , 250 , 251 , 252 , 253 , 256 , 257 , 258 , 260 , 262 , 263 , 264 , 266 , 268 , 269 , 270 , 271 , 272 , 273 , 274 , 276 , 863 , 873 , 880 , 1138 ) , HEL (erythroid) ( 1031 ) , HeLa (cervical) ( 11 , 21 , 27 , 113 , 287 , 293 , 334 , 374 , 425 , 756 , 800 , 830 , 962 , 1057 , 1110 , 1147 ) , HeLa S3 (cervical) ( 749 ) , hepatic-'liver, para-cholangiocellular carcinoma tissue' ( 533 , 545 , 699 , 708 ) , hepatic-'liver, para-hepatocellular carcinoma tissue' ( 523 , 525 , 526 , 528 , 537 , 538 , 540 , 541 , 542 , 546 , 548 , 549 , 551 , 553 , 554 , 555 , 556 , 557 , 559 , 560 , 564 , 566 , 568 , 692 , 693 , 695 , 697 , 698 , 709 , 831 , 833 , 838 , 839 , 843 , 846 , 847 , 892 ) , hepatocyte-liver ( 3 , 522 , 524 , 527 , 534 , 535 , 536 , 539 , 543 , 547 , 550 , 561 , 567 , 691 , 696 , 700 , 841 , 842 , 845 ) , HepG2 (hepatic) ( 285 , 403 , 574 , 1057 , 1142 ) , HES-3 ('stem, embryonic') ( 289 ) , HL60 (myeloid) ( 7 ) , HLF (hepatic) ( 572 ) , HMVEC (endothelial) ( 1140 ) , HOS (bone cell) ( 901 ) , HU-3 (myeloid) ( 1102 ) , HuCCT1 (hepatic) ( 796 ) , Huh1 (hepatic) ( 702 ) , Huh28 (hepatic) ( 751 ) , Huh7 (hepatic) ( 798 ) , HUT-78 (T lymphocyte) ( 1024 ) , HUVEC (endothelial) ( 17 , 18 , 19 , 49 , 765 , 766 , 767 , 768 , 769 , 770 , 771 , 772 , 795 , 949 , 1065 , 1098 , 1103 ) , IMR-90 (fibroblast) ( 2 ) , IMR32 (neural crest) ( 9 , 990 ) , J82 (bladder cell) ( 1001 ) , JHH-2 (hepatic) ( 752 ) , JHH-4 (hepatic) ( 728 ) , JHH-7 (hepatic) ( 750 ) , JPM50.6 (T lymphocyte) ( 963 ) , Jurkat (T lymphocyte) ( 39 , 52 , 57 , 76 , 77 , 78 , 86 , 87 , 88 , 89 , 90 , 91 , 92 , 93 , 94 , 102 , 103 , 105 , 106 , 107 , 108 , 109 , 110 , 111 , 114 , 115 , 116 , 117 , 118 , 119 , 120 , 121 , 122 , 126 , 129 , 130 , 131 , 132 , 133 , 134 , 135 , 136 , 137 , 138 , 139 , 140 , 141 , 142 , 143 , 144 , 145 , 146 , 147 , 148 , 149 , 150 , 151 , 152 , 153 , 154 , 155 , 156 , 157 , 158 , 159 , 160 , 161 , 162 , 163 , 164 , 165 , 166 , 167 , 168 , 169 , 172 , 173 , 174 , 178 , 191 , 192 , 193 , 211 , 212 , 213 , 214 , 215 , 234 , 235 , 236 , 237 , 244 , 293 , 306 , 307 , 308 , 309 , 323 , 333 , 337 , 338 , 339 , 340 , 341 , 342 , 344 , 345 , 368 , 369 , 401 , 404 , 433 , 465 , 488 , 489 , 490 , 491 , 492 , 493 , 494 , 507 , 508 , 509 , 511 , 512 , 513 , 514 , 516 , 517 , 529 , 530 , 531 , 532 , 570 , 573 , 587 , 674 , 675 , 688 , 689 , 706 , 707 , 722 , 723 , 745 , 746 , 748 , 757 , 782 , 801 , 802 , 803 , 804 , 805 , 806 , 811 , 815 , 816 , 820 , 821 , 822 , 823 , 824 , 825 , 826 , 827 , 828 , 835 , 836 , 837 , 840 , 844 , 891 , 906 , 948 , 963 , 1024 , 1069 , 1082 , 1109 , 1115 , 1117 , 1126 , 1127 ) , Jurkat E6-1 (T lymphocyte) ( 44 ) , K562 (erythroid) ( 42 , 99 , 100 , 101 , 277 , 278 , 279 , 280 , 281 , 282 , 283 , 331 , 332 , 395 , 399 , 402 , 410 , 421 , 422 , 423 , 424 , 426 , 428 , 429 , 430 , 431 , 432 , 441 , 442 , 443 , 461 , 872 ) , Karpas-1106P (B lymphocyte) ( 1046 ) , keratinocyte ( 899 ) , kidney ( 503 , 515 , 518 , 519 , 520 ) , KMS-27 (B lymphocyte) ( 1049 ) , KY821 (myeloid) ( 292 ) , Kyse140 (esophageal) ( 379 ) , Kyse150 (esophageal) ( 375 ) , Kyse270 (esophageal) ( 377 ) , Kyse30 (esophageal) ( 372 ) , Kyse410 (esophageal) ( 378 , 1040 ) , Kyse510 (esophageal) ( 1039 ) , Kyse520 (esophageal) ( 376 ) , L428 (lymphoid) ( 985 , 1025 ) , L540 (lymphoid) ( 371 ) , LAN-5 (neural crest) ( 9 , 978 ) , LAN-6 (neural crest) ( 9 , 303 , 807 , 808 , 809 , 810 ) , larynx ( 854 ) , LCLC-103H (pulmonary) ( 1009 ) , liver ( 3 , 288 , 352 , 353 , 358 , 361 , 363 , 364 , 365 , 367 , 501 , 502 , 504 , 505 , 506 , 552 , 558 , 563 , 690 , 832 , 889 ) , LLC-PK1 (epithelial) ( 1086 ) , LN18 (glial) ( 799 , 812 , 813 , 814 , 887 , 888 , 1063 ) , LN405 (glial) ( 1003 ) , LN428_LNZ308 (glial) [EGFR (human), transfection, EGFR (wildtype)] ( 245 ) , LN428_LNZ308 (glial) [EGFR (human), transfection, EGFRvIII mutant (aka Delta EGFR, d2-7 EGFR; del. exon 2-7; in-frame loss 801 bp/267 aa in EC domain)] ( 245 ) , LN428_LNZ308 (glial) [EGFR (human), transfection, EGFRvIII-ki mutant (deletion of exons 2-7 plus kinase inactive mutation)] ( 245 ) , LN444 (glial) ( 462 , 463 ) , LNCaP (prostate cell) ( 310 , 403 ) , LOU-NH91 (squamous) ( 34 ) , LoVo (intestinal) ( 403 ) , lung ( 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 194 , 195 , 196 , 197 , 198 , 199 , 200 , 201 , 202 , 203 , 204 , 205 , 206 , 207 , 208 , 209 , 210 , 238 , 239 , 240 , 241 , 242 , 243 , 350 , 351 , 383 , 385 , 386 , 387 , 388 , 389 , 390 , 391 , 392 , 393 , 394 , 396 , 397 , 398 , 400 , 405 , 406 , 444 , 445 , 446 , 447 , 448 , 449 , 450 , 451 , 452 , 453 , 454 , 455 , 456 , 457 , 458 , 459 , 460 , 575 , 576 , 577 , 578 , 581 , 582 , 681 , 715 , 716 , 717 , 718 , 719 , 720 , 721 , 755 , 759 , 760 , 788 , 793 , 794 , 953 , 954 , 955 , 956 , 957 , 959 , 960 , 961 , 965 , 966 , 996 , 1013 , 1028 , 1029 , 1041 , 1042 , 1044 , 1048 , 1050 , 1052 , 1055 , 1064 , 1070 , 1071 , 1076 , 1078 , 1079 , 1080 , 1081 , 1092 , 1100 , 1107 ) , LXF-289 (pulmonary) ( 1010 ) , M059J (glial) ( 1062 ) , M14-MEL (melanocyte) ( 1056 ) , MCF-7 (breast cell) ( 311 , 403 , 774 , 928 , 1037 , 1128 , 1134 ) , MCF10A1 (epithelial) ( 4 ) , MDA-MB-231 (breast cell) ( 48 , 302 , 521 , 928 ) , MDA-MB-361 (breast cell) ( 586 ) , MDA-MB-435S (breast cell) ( 571 ) , ME-F2 (myeloid) ( 1038 ) , MEF (fibroblast) ( 915 ) , MEF (fibroblast) [JNK1 (human)] ( 848 ) , MEF (fibroblast) [Myc (mouse)] ( 1056 ) , mesangial ( 1112 ) , MG63 (bone cell) ( 1142 ) , MHH-NB-11 (neural crest) ( 1004 ) , MKN-1 (gastric) ( 886 ) , MKN-45 (gastric) ( 46 , 58 , 64 , 65 , 66 , 67 , 68 , 69 , 70 , 71 , 72 , 123 , 124 , 125 , 170 , 305 , 343 , 373 , 896 ) , MM (B lymphocyte) ( 1108 ) , MOLT-4 (T lymphocyte) ( 1024 ) , monocyte ( 25 , 1137 ) , MRC5 (fibroblast) ( 8 ) , MV4-11 (macrophage) ( 571 ) , myeloid-bone marrow ( 997 , 998 , 1014 ) , NCI-H128 (pulmonary) ( 29 ) , NCI-H1299 (pulmonary) ( 32 , 427 ) , NCI-H1355 (pulmonary) ( 31 ) , NCI-H1417 (pulmonary) ( 29 ) , NCI-H1435 (pulmonary) ( 1067 ) , NCI-H1437 (pulmonary) ( 36 , 37 , 1094 ) , NCI-H1568 (pulmonary) ( 1093 ) , NCI-H1650 (pulmonary) ( 33 , 59 , 60 , 61 , 62 , 63 , 179 , 182 , 183 , 1124 ) , NCI-H1666 (pulmonary) ( 37 ) , NCI-H1693 (pulmonary) ( 1084 ) , NCI-H1703 (squamous) ( 34 , 47 , 82 , 588 , 589 , 590 , 591 , 940 , 941 , 1106 , 1123 ) , NCI-H1734 (pulmonary) ( 32 ) , NCI-H1781 (pulmonary) ( 35 , 988 ) , NCI-H1792 (pulmonary) ( 31 ) , NCI-H1838 (pulmonary) ( 1012 , 1058 ) , NCI-H1944 (pulmonary) ( 32 , 1090 , 1095 ) , NCI-H1975 (pulmonary) ( 33 , 1116 ) , NCI-H2023 (pulmonary) ( 1083 ) , NCI-H2030 (pulmonary) ( 1060 ) , NCI-H2052 (pulmonary) ( 1011 ) , NCI-H2073 (pulmonary) ( 34 , 36 ) , NCI-H209 (pulmonary) ( 29 , 36 ) , NCI-H2106 (pulmonary) ( 33 ) , NCI-H2172 (pulmonary) ( 1087 ) , NCI-H2228 (pulmonary) ( 35 , 40 ) , NCI-H23 (pulmonary) ( 31 ) , NCI-H2342 (pulmonary) ( 34 ) , NCI-H2405 (pulmonary) ( 37 ) , NCI-H292 (pulmonary) ( 127 , 370 ) , NCI-H3122 (pulmonary) ( 35 , 184 ) , NCI-H358 (pulmonary) ( 32 ) , NCI-H441 (pulmonary) ( 31 ) , NCI-H446 (pulmonary) ( 30 ) , NCI-H460 (pulmonary) ( 32 ) , NCI-H524 (pulmonary) ( 29 ) , NCI-H526 (pulmonary) ( 30 ) , NCI-H596 (pulmonary) ( 1030 ) , NCI-H661 (pulmonary) ( 35 , 1091 ) , NCI-H69 (pulmonary) ( 30 ) , NCI-H82 (pulmonary) ( 30 ) , NCI-H838 (pulmonary) ( 36 ) , neuron-brain ( 1121 ) , NSCLC (pulmonary) ( 403 ) , NUGC-2 (gastric) ( 894 ) , OCI/AML3 (myeloid) ( 7 ) , OPM-1 (B lymphocyte) ( 1007 , 1008 ) , ovary ( 314 , 315 , 316 , 317 , 318 , 319 , 320 , 324 , 381 , 382 , 407 , 409 , 411 , 412 , 413 , 414 , 415 , 416 , 417 , 418 , 419 , 907 , 908 , 910 , 911 , 912 , 913 , 914 ) , OVCAR3 (ovarian) ( 2 ) , OVMANA (ovarian) ( 246 , 295 , 297 ) , OVMIU (ovarian) ( 296 ) , OVTOKO (ovarian) ( 299 , 321 , 322 ) , P815 (mast) ( 1132 ) , PANC-1 (pancreatic) ( 336 ) , pancreas ( 584 , 874 , 1119 , 1122 ) , PC3 (prostate cell) ( 2 , 753 , 1057 ) , PC9-TAR (pulmonary) ( 972 ) , PLC/PRF/5 (hepatic) ( 701 ) , RAMOS (B lymphocyte) ( 1136 ) , RC-K8 (B lymphocyte) ( 1045 ) , RMUG-S (ovarian) ( 298 ) , SACC-83 (salivary gland) ( 762 , 764 ) , salivary gland ( 732 , 733 , 734 , 735 , 736 , 737 , 738 , 739 , 740 , 741 , 742 , 743 , 744 ) , Saos-2 (bone cell) ( 51 , 510 , 754 ) , SEM (B lymphocyte) ( 999 ) , SH-SY5Y (neural crest) ( 9 , 20 , 300 , 301 , 326 , 327 , 915 , 1054 ) , SJSA-1 (bone cell) ( 925 ) , SK-HEP-1 (endothelial) ( 677 ) , SK-LMS-1 (muscle cell) ( 51 ) , SK-MES-1 (pulmonary) ( 1 ) , SKBr3 (breast cell) ( 403 ) , skin ( 346 , 434 , 435 , 436 , 437 , 438 , 439 , 440 , 713 , 724 , 725 , 726 , 727 , 747 , 817 , 818 , 819 ) , SKNBE(2) (neural crest) ( 882 , 883 ) , SKNFI (neural crest) ( 9 , 1005 ) , SKNSH (neural crest) ( 1051 ) , SKOV-3 (ovarian) ( 2 ) , SMS-KCN (neural crest) ( 9 , 902 , 903 , 904 , 905 ) , SMS-KCN-A (neural crest) ( 9 , 304 ) , SNB-19 (glial) ( 1053 ) , SNU-1079 (hepatic) ( 731 ) , SNU-1196 (hepatic) ( 729 ) , SNU-182 (hepatic) ( 797 ) , SNU-398 (hepatic) ( 730 ) , SNU-449 (hepatic) ( 676 ) , SNU-C2B (intestinal) ( 1015 , 1016 ) , stomach ( 466 , 467 , 468 , 469 , 470 , 471 , 472 , 473 , 474 , 475 , 476 , 477 , 478 , 479 , 480 , 481 , 482 , 483 , 484 , 485 , 486 , 487 , 775 , 776 , 777 , 778 , 779 , 780 , 781 , 783 , 784 , 785 , 786 , 787 , 789 , 790 , 791 , 792 , 868 , 869 , 870 , 871 , 876 , 877 , 878 , 879 , 881 , 884 ) , SW-1573 (pulmonary) ( 897 ) , SW1710 (bladder cell) ( 970 ) , SW480 (intestinal) ( 335 ) , SW620 (intestinal) ( 335 ) , SW780 (bladder cell) ( 969 ) , T98G (glial) ( 1075 ) , THP1 (myeloid) ( 7 ) , thymus ( 217 , 218 , 219 , 220 ) , thyroid ( 829 , 862 , 890 ) , TS (lymphocyte) ( 1068 ) , U-118MG (glial) ( 180 , 181 , 189 ) , U251 (glial) ( 328 ) , U2OS (bone cell) ( 51 , 899 , 951 ) , U87MG (glial) ( 958 ) , UT-7 (myeloid) ( 1104 ) , XG2 (B lymphocyte) ( 1043 )

Upstream Regulation
Regulatory protein:
Abl (human) ( 49 ) , Akt1 (human) ( 20 ) , Alix (human) ( 2 ) , ANG (human) ( 12 ) , ARAF (human) ( 915 ) , ASK1 (human) ( 947 ) , CAD (human) ( 10 ) , CARD11 (human) ( 963 ) , DUSP6 (human) ( 1037 ) , DYN2 (human) ( 1109 ) , E4 (adenovirus) ( 774 ) , FAT (human) ( 1086 ) , HRas (human) ( 1111 ) , HSP27 (human) ( 756 ) , IKKB (human) ( 834 ) , JIP3 (human) ( 899 , 1089 ) , JNK1 (human) ( 848 , 1134 , 1146 ) , JNK1 (mouse) ( 13 ) , JNK2 (human) ( 286 , 1134 ) , KRas (human) ( 1111 ) , LIME1 (mouse) ( 1126 ) , MEKK6 (human) ( 947 ) , MKK3 (human) ( 915 ) , MKK4 (human) ( 1065 ) , MKK7 (human) ( 1146 ) , MST1 (human) ( 293 , 336 ) , MUC16 (human) ( 75 ) , MUC4 (human) ( 1027 ) , NDFIP1 (human) ( 334 ) , NDFIP2 (human) ( 334 ) , NPM-ALK (human) ( 284 ) , p63 (human) ( 864 ) , PEA-15 (human) ( 328 ) , PGAM5 (human) ( 569 ) , PHLPP (human) ( 336 ) , PHLPP2 (human) ( 336 ) , Pim1 (human) ( 427 ) , PKCE (human) ( 310 ) , PPP1CA (human) ( 758 ) , PPP2CA (human) ( 758 ) , PRR7 (human) ( 178 ) , PTP1B (mouse) ( 773 ) , Pyk2 (human) ( 1145 ) , RAF1 (human) ( 2 ) , Ret (human) ( 190 , 311 ) , ROCK1 (human) ( 899 ) , STAT3 (human) ( 1146 ) , TRIM45 (human) ( 11 ) , WNK1 (human) ( 962 ) , yopJ (bacteria) ( 1022 )
Putative in vivo kinases:
ASK1 (human) ( 427 ) , MEKK6 (human) ( 947 ) , MKK4 (human) ( 1089 ) , MKK7 (human) ( 1141 , 1147 )
Kinases, in vitro:
MKK4 (human) ( 1148 ) , MKK7 (human) ( 1147 ) , Ret (human) ( 1088 )
Putative upstream phosphatases:
PPP5C (human) ( 1118 )
Treatments:
1,25D ( 7 ) , 14,15-EETs ( 285 ) , 15d-PGJ2 ( 795 ) , 4-HT ( 403 , 915 ) , 9F7-F11 ( 5 ) , ABT-737 ( 10 ) , adriamycin ( 2 , 510 ) , amino_acid_starvation ( 848 ) , amino_acids ( 1125 ) , anisomycin ( 20 , 889 , 1097 , 1125 ) , anti-CD3 ( 1145 ) , anti-CD3/CD28 ( 26 , 963 , 1117 , 1145 ) , anti-CD40 ( 1136 ) , anti-CD8 ( 1126 ) , anti-IgM ( 1120 ) , anti-TCR ( 178 ) , antigenic stimulation ( 1109 , 1133 ) , arsenic ( 19 ) , arsenite ( 1134 ) , bacterial infection ( 758 ) , black_tea_polyphenols ( 1098 ) , blood pressure ( 1138 ) , BMP2 ( 952 ) , bortezomib ( 1108 ) , bumetanide ( 962 ) , C2-ceramide ( 749 ) , C2-DHCer ( 749 ) , calphostin_C ( 1103 ) , calyculin_A ( 758 , 962 ) , catalase ( 19 ) , Cd(2+) ( 1144 ) , cGMP_analog ( 335 ) , cimetidine ( 1129 ) , cisplatin ( 510 ) , colchicine ( 1134 ) , colforsin ( 964 , 1138 ) , compound_1 ( 25 ) , CTGF ( 1112 ) , culturing_of_cells ( 1119 ) , DCVC ( 1086 ) , defactinib ( 1 ) , dexamethasone ( 420 , 951 , 964 ) , dimethylfumarate ( 17 ) , dronabinol ( 897 , 1024 ) , EGCG ( 19 ) , EGF ( 334 , 425 , 754 , 897 , 952 , 1065 , 1139 , 1146 ) , estradiol ( 1037 ) , etoposide ( 293 , 510 ) , GBS ( 1137 ) , GDNF ( 311 ) , glabridin ( 104 ) , glucose_starvation ( 1089 ) , Go_6976 ( 1103 ) , Go_6983 ( 1103 ) , H2O2 ( 569 , 947 , 962 , 1056 , 1077 , 1103 ) , HGF ( 176 , 773 ) , high_glucose ( 18 ) , histamine ( 1129 ) , hypertonic_buffer ( 952 ) , hypotonic_buffer ( 962 ) , hypoxia ( 1118 ) , IFN-gamma ( 1119 ) , IGF-1 ( 962 , 1119 ) , IL-1a ( 1022 , 1132 , 1140 ) , IL-1b ( 25 , 756 , 1057 , 1119 ) , IL-4 ( 1136 ) , IL-6 ( 949 ) , imatinib ( 49 , 190 ) , insulin ( 18 , 834 , 889 , 898 , 949 , 952 , 1125 , 1138 ) , IOA ( 928 ) , ionizing_radiation ( 328 ) , ionomycin ( 26 , 963 , 1127 ) , ischemia ( 24 ) , JNK_inhibitor_I ( 949 , 1018 ) , K252a ( 1112 ) , KCl ( 962 ) , low_birth_weight ( 898 ) , LY2090314 ( 16 ) , LY294002 ( 49 , 1018 ) , mepyramine ( 1129 ) , MG132 ( 1019 ) , N65828 ( 12 ) , NAC ( 795 ) , neuregulin ( 5 ) , nocodazole ( 1134 ) , NSC23766 ( 774 ) , NVP-BKM120 ( 1 ) , okadaic_acid ( 464 , 758 , 1125 ) , palmitate ( 285 ) , PAR2-activating_peptide ( 521 ) , PD98059 ( 949 , 1037 ) , PDGF ( 1018 ) , phorbol_ester ( 26 , 38 , 962 , 963 , 1127 , 1130 , 1138 , 1140 ) , plumbagin ( 1023 ) , pneumolysin ( 758 ) , PP1 ( 190 , 521 ) , PP3 ( 521 ) , PTX ( 1024 ) , Q-VD-OPh ( 10 ) , rapamycin ( 311 , 964 , 1125 ) , resiquimod ( 25 ) , salicylate ( 1130 ) , SB202190 ( 425 ) , SB203580 ( 311 , 889 , 950 , 952 , 1086 ) , SB415286 ( 7 ) , secramine_A ( 774 ) , serum ( 11 , 1097 ) , siRNA ( 834 , 1118 , 1134 ) , sorafenib ( 190 ) , sorbitol ( 113 , 286 , 951 , 962 , 963 ) , SP600125 ( 8 , 19 , 311 , 464 , 754 , 889 , 950 , 952 , 964 , 1018 , 1077 , 1086 , 1119 , 1130 , 1134 ) , staurosporine ( 1103 ) , TAK1_inhibitor ( 15 ) , tamoxifen ( 1037 ) , taxol ( 13 ) , TFF-2 ( 1139 ) , TGF-beta ( 952 ) , TNF ( 17 , 21 , 310 , 756 , 834 , 950 , 962 , 1103 , 1119 , 1130 , 1140 , 1141 ) , U0126 ( 44 , 311 , 425 , 964 ) , UV ( 38 , 420 , 899 , 952 , 1110 , 1149 ) , vanadate ( 758 , 962 ) , VEGF ( 49 ) , vinblastine ( 1134 ) , virus infection ( 8 , 982 ) , withaferin_A ( 950 ) , wortmannin ( 311 , 1018 , 1119 ) , WR1065 ( 1128 ) , Y27632 ( 774 , 899 ) , Z-VAD-FMK ( 1119 )

Downstream Regulation
Effects of modification on JNK1:
enzymatic activity, induced ( 1145 , 1147 , 1149 )
Effects of modification on biological processes:
apoptosis, altered ( 1086 ) , apoptosis, induced ( 947 ) , cell adhesion, altered ( 1086 ) , transcription, altered ( 1147 )

References 

1

Cavazzoni A, et al. (2017) Enhanced efficacy of AKT and FAK kinase combined inhibition in squamous cell lung carcinomas with stable reduction in PTEN. Oncotarget 8, 53068-53083
28881794   Curated Info

2

Ma SQ, et al. (2017) The lack of Raf-1 kinase feedback regulation enhances antiapoptosis in cancer cells. Oncogene 36, 2014-2022
27841865   Curated Info

3

Moles A, et al. (2016) A RelA(p65) Thr505 phospho-site mutation reveals an important mechanism regulating NF-κB-dependent liver regeneration and cancer. Oncogene 35, 4623-32
26853469   Curated Info

4

Kim DY, Helfman DM (2016) Loss of MLCK leads to disruption of cell-cell adhesion and invasive behavior of breast epithelial cells via increased expression of EGFR and ERK/JNK signaling. Oncogene 35, 4495-508
26876209   Curated Info

5

Le Clorennec C, et al. (2016) The anti-HER3 (ErbB3) therapeutic antibody 9F7-F11 induces HER3 ubiquitination and degradation in tumors through JNK1/2- dependent ITCH/AIP4 activation. Oncotarget 7, 37013-37029
27203743   Curated Info

6

Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62
27251275   Curated Info

7

Gupta K, et al. (2016) GSK-3 Inhibition Sensitizes Acute Myeloid Leukemia Cells to 1,25D-Mediated Differentiation. Cancer Res 76, 2743-53
26964622   Curated Info

8

Klein SR, et al. (2015) C-Jun N-terminal kinases are required for oncolytic adenovirus-mediated autophagy. Oncogene 34, 5295-301
25619840   Curated Info

9

Palacios-Moreno J, et al. (2015) Neuroblastoma Tyrosine Kinase Signaling Networks Involve FYN and LYN in Endosomes and Lipid Rafts. PLoS Comput Biol 11, e1004130
25884760   Curated Info

10

Ichim G, et al. (2015) Limited mitochondrial permeabilization causes DNA damage and genomic instability in the absence of cell death. Mol Cell 57, 860-72
25702873   Curated Info

11

Sato T, et al. (2015) The TRIM-FLMN protein TRIM45 directly interacts with RACK1 and negatively regulates PKC-mediated signaling pathway. Oncogene 34, 1280-91
24681954   Curated Info

12

Miyake M, et al. (2015) Angiogenin promotes tumoral growth and angiogenesis by regulating matrix metallopeptidase-2 expression via the ERK1/2 pathway. Oncogene 34, 890-901
24561529   Curated Info

13

Yin B, et al. (2015) The TrkB+ cancer stem cells contribute to post-chemotherapy recurrence of triple-negative breast cancers in an orthotopic mouse model. Oncogene 34, 761-70
24531713   Curated Info

14

Carpenter RL, Paw I, Dewhirst MW, Lo HW (2015) Akt phosphorylates and activates HSF-1 independent of heat shock, leading to Slug overexpression and epithelial-mesenchymal transition (EMT) of HER2-overexpressing breast cancer cells. Oncogene 34, 546-57
24469056   Curated Info

15

Huang HL, Chiang CH, Hung WC, Hou MF (2015) Targeting of TGF-β-activated protein kinase 1 inhibits chemokine (C-C motif) receptor 7 expression, tumor growth and metastasis in breast cancer. Oncotarget 6, 995-1007
25557171   Curated Info

16

Atkinson JM, et al. (2015) Activating the Wnt/β-Catenin Pathway for the Treatment of Melanoma--Application of LY2090314, a Novel Selective Inhibitor of Glycogen Synthase Kinase-3. PLoS One 10, e0125028
25915038   Curated Info

17

Gerhardt S, et al. (2015) Dimethylfumarate protects against TNF-α-induced secretion of inflammatory cytokines in human endothelial cells. J Inflamm (Lond) 12, 49
26246800   Curated Info

18

De Nigris V, et al. (2015) Short-term high glucose exposure impairs insulin signaling in endothelial cells. Cardiovasc Diabetol 14, 114
26297582   Curated Info

19

Kim JY, et al. (2015) The Green Tea Component (-)-Epigallocatechin-3-Gallate Sensitizes Primary Endothelial Cells to Arsenite-Induced Apoptosis by Decreasing c-Jun N-Terminal Kinase-Mediated Catalase Activity. PLoS One 10, e0138590
26375285   Curated Info

20

Fey D, et al. (2015) Signaling pathway models as biomarkers: Patient-specific simulations of JNK activity predict the survival of neuroblastoma patients. Sci Signal 8, ra130
26696630   Curated Info

21

Park B (2014) JNK1‑mediated phosphorylation of Smac/DIABLO at the serine 6 residue is functionally linked to its mitochondrial release during TNF‑α-‑induced apoptosis of HeLa cells. Mol Med Rep 10, 3205-10
25310587   Curated Info

22

Johnson H, White FM (2014) Quantitative analysis of signaling networks across differentially embedded tumors highlights interpatient heterogeneity in human glioblastoma. J Proteome Res 13, 4581-93
24927040   Curated Info

23

Tian H, et al. (2014) MDA-7/IL-24 inhibits Nrf2-mediated antioxidant response through activation of p38 pathway and inhibition of ERK pathway involved in cancer cell apoptosis. Cancer Gene Ther 21, 416-26
25236495   Curated Info

24

Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704
24719451   Curated Info

25

Cushing L, et al. (2014) Interleukin 1/Toll-like receptor-induced autophosphorylation activates interleukin 1 receptor-associated kinase 4 and controls cytokine induction in a cell type-specific manner. J Biol Chem 289, 10865-75
24567333   Curated Info

26

Yang CY, et al. (2014) Dual-Specificity Phosphatase 14 (DUSP14/MKP6) Negatively Regulates TCR Signaling by Inhibiting TAB1 Activation. J Immunol 192, 1547-57
24403530   Curated Info

27

Zhou Y, et al. (2014) p38-Mediated phosphorylation of Eps15 endocytic adaptor protein. FEBS Lett 588, 131-7
24269888   Curated Info

28

Arneja A, et al. (2014) Qualitatively different T cell phenotypic responses to IL-2 versus IL-15 are unified by identical dependences on receptor signal strength and duration. J Immunol 192, 123-35
24298013   Curated Info

29

Rikova K, Hall B (2013) CST Curation Set: 20734, 21161, 30112, 30153, 30154; Year: 2013; Biosample/Treatment: cell line, H1417, DMS79, H128, H209, H524; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

30

Rikova K, Hall B (2013) CST Curation Set: 20735, 21162, 30155, 30156, 30157; Year: 2013; Biosample/Treatment: cell line, DMS53, H526, H69, H82, H446; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

31

Rikova K, Hall B (2013) CST Curation Set: 20736, 21163, 30158, 30159, 30160; Year: 2013; Biosample/Treatment: cell line, A549, H1355, H23, H441, H1792; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

32

Rikova K, Hall B (2013) CST Curation Set: 20737, 21164, 30161, 30162, 30163; Year: 2013; Biosample/Treatment: cell line, H1299, H1944, H358, H1734, H460; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

33

Rikova K, Hall B (2013) CST Curation Set: 20738, 21165, 30164, 30165, 30166; Year: 2013; Biosample/Treatment: cell line, H1650, HCC827, H1975, Calu-3, H2106; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

34

Rikova K, Hall B (2013) CST Curation Set: 20739, 21166, 30167, 30168, 30169; Year: 2013; Biosample/Treatment: cell line, H2342, H2073, Lou-NH91, HCC15, H1703; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

35

Rikova K, Hall B (2013) CST Curation Set: 20740, 21167, 30170, 30171, 30172; Year: 2013; Biosample/Treatment: cell line, H2228, H3122, HCC78, H661, H1781; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

36

Rikova K, Hall B (2013) CST Curation Set: 20742, 21169, 30176, 30177, 30178; Year: 2013; Biosample/Treatment: cell line, H838, DMS153, H2073, H209, H1437; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

37

Rikova K, Hall B (2013) CST Curation Set: 20741, 21168, 30173, 30174, 30175; Year: 2013; Biosample/Treatment: cell line, H1666, CAL-12T, H2405, HCC44, H1437; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

38

Gandin V, et al. (2013) Degradation of newly synthesized polypeptides by ribosome-associated RACK1/c-Jun N-terminal kinase/eukaryotic elongation factor 1A2 complex. Mol Cell Biol 33, 2510-26
23608534   Curated Info

39

Mertins P, et al. (2013) Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat Methods 10, 634-7
23749302   Curated Info

40

Rikova K (2013) CST Curation Set: 18449; Year: 2012; Biosample/Treatment: cell line, H2228/crizotinib, geldanamycin; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine (P-Tyr-1000) MultiMab(TM) Rabbit mAb mix Cat#: 8954
Curated Info

41

Johnson H, Lescarbeau RS, Gutierrez JA, White FM (2013) Phosphotyrosine profiling of NSCLC cells in response to EGF and HGF reveals network specific mediators of invasion. J Proteome Res 12, 1856-67
23438512   Curated Info

42

Zhou H, et al. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome. J Proteome Res 12, 260-71
23186163   Curated Info

43

Song JY, et al. (2013) Wip1 suppresses apoptotic cell death through direct dephosphorylation of BAX in response to γ-radiation. Cell Death Dis 4, e744
23907458   Curated Info

44

Helou YA, Nguyen V, Beik SP, Salomon AR (2013) ERK positive feedback regulates a widespread network of tyrosine phosphorylation sites across canonical T cell signaling and actin cytoskeletal proteins in Jurkat T cells. PLoS One 8, e69641
23874979   Curated Info

45

Rikova K (2012) CST Curation Set: 16140; Year: 2012; Biosample/Treatment: cell line, A549/iressa, gleevec, crizotinib; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine (P-Tyr-1000) MultiMab(TM) Rabbit mAb mix Cat#: 8954
Curated Info

46

Rikova K (2012) CST Curation Set: 16137; Year: 2012; Biosample/Treatment: cell line, MKN45/crizotinib; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine (P-Tyr-1000) MultiMab(TM) Rabbit mAb mix Cat#: 8954
Curated Info

47

Rikova K (2012) CST Curation Set: 16139; Year: 2012; Biosample/Treatment: cell line, H1703/gleevec; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine (P-Tyr-1000) MultiMab(TM) Rabbit mAb mix Cat#: 8954
Curated Info

48

Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68
22617229   Curated Info

49

Anselmi F, et al. (2012) c-ABL modulates MAP kinases activation downstream of VEGFR-2 signaling by direct phosphorylation of the adaptor proteins GRB2 and NCK1. Angiogenesis 15, 187-97
22327338   Curated Info

50

Manser C, et al. (2012) Lemur tyrosine kinase-2 signalling regulates kinesin-1 light chain-2 phosphorylation and binding of Smad2 cargo. Oncogene 31, 2773-82
21996745   Curated Info

51

Bai Y, et al. (2012) Phosphoproteomics identifies driver tyrosine kinases in sarcoma cell lines and tumors. Cancer Res 72, 2501-11
22461510   Curated Info

52

Zhou J (2012) CST Curation Set: 14432; Year: 2012; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine (P-Tyr-1000) Rabbit mAb Cat#: 8954, Phospho-Tyrosine Rabbit mAb (p-Tyr-1000) Immunoaffinity Beads Cat#: 8876
Curated Info

53

Stokes MP, et al. (2012) PTMScan Direct: Identification and Quantification of Peptides from Critical Signaling Proteins by Immunoaffinity Enrichment Coupled with LC-MS/MS. Mol Cell Proteomics 11, 187-201
22322096   Curated Info

54

Beli P, et al. (2012) Proteomic Investigations Reveal a Role for RNA Processing Factor THRAP3 in the DNA Damage Response. Mol Cell 46, 212-25
22424773   Curated Info

55

Rikova K (2012) CST Curation Set: 14270; Year: 2012; Biosample/Treatment: cell line, Tumor pilot study 1mg/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

56

Rikova K (2012) CST Curation Set: 14271; Year: 2012; Biosample/Treatment: cell line, Tumor pilot study 2mg/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

57

Zhou J (2012) CST Curation Set: 14185; Year: 2012; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine (P-Tyr-1000) Rabbit mAb Cat#: 8954, Phospho-Tyrosine Rabbit mAb (p-Tyr-1000) Immunoaffinity Beads Cat#: 8876
Curated Info

58

Zhou J (2012) CST Curation Set: 14105; Year: 2012; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine (P-Tyr-1000) Rabbit mAb Cat#: 8954, Phospho-Tyrosine Rabbit mAb (p-Tyr-1000) Immunoaffinity Beads Cat#: 8876
Curated Info

59

Possemato A (2012) CST Curation Set: 14060; Year: 2012; Biosample/Treatment: cell line, H1650/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

60

Possemato A (2012) CST Curation Set: 14061; Year: 2012; Biosample/Treatment: cell line, H1650/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

61

Possemato A (2012) CST Curation Set: 14063; Year: 2012; Biosample/Treatment: cell line, H1650/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

62

Possemato A (2012) CST Curation Set: 14058; Year: 2012; Biosample/Treatment: cell line, H1650/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

63

Possemato A (2012) CST Curation Set: 14059; Year: 2012; Biosample/Treatment: cell line, H1650/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

64

Zhou J (2012) CST Curation Set: 13888; Year: 2012; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine (P-Tyr-1000) Rabbit mAb Cat#: 8954, Phospho-Tyrosine Rabbit mAb (p-Tyr-1000) Immunoaffinity Beads Cat#: 8876
Curated Info

65

Zhou J (2012) CST Curation Set: 13889; Year: 2012; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine (P-Tyr-1000) Rabbit mAb Cat#: 8954, Phospho-Tyrosine Rabbit mAb (p-Tyr-1000) Immunoaffinity Beads Cat#: 8876
Curated Info

66

Zhou J (2012) CST Curation Set: 13898; Year: 2012; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine (P-Tyr-1000) Rabbit mAb Cat#: 8954, Phospho-Tyrosine Rabbit mAb (p-Tyr-1000) Immunoaffinity Beads Cat#: 8876
Curated Info

67

Zhou J (2012) CST Curation Set: 13899; Year: 2012; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine (P-Tyr-1000) Rabbit mAb Cat#: 8954, Phospho-Tyrosine Rabbit mAb (p-Tyr-1000) Immunoaffinity Beads Cat#: 8876
Curated Info

68

Zhou J (2012) CST Curation Set: 13886; Year: 2012; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine (P-Tyr-1000) Rabbit mAb Cat#: 8954, Phospho-Tyrosine Rabbit mAb (p-Tyr-1000) Immunoaffinity Beads Cat#: 8876
Curated Info

69

Zhou J (2012) CST Curation Set: 13887; Year: 2012; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine (P-Tyr-1000) Rabbit mAb Cat#: 8954, Phospho-Tyrosine Rabbit mAb (p-Tyr-1000) Immunoaffinity Beads Cat#: 8876
Curated Info

70

Zhou J (2012) CST Curation Set: 13838; Year: 2012; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine (P-Tyr-1000) Rabbit mAb Cat#: 8954, Phospho-Tyrosine Rabbit mAb (p-Tyr-1000) Immunoaffinity Beads Cat#: 8876
Curated Info

71

Zhou J (2012) CST Curation Set: 13840; Year: 2012; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine (P-Tyr-1000) Rabbit mAb Cat#: 8954, Phospho-Tyrosine Rabbit mAb (p-Tyr-1000) Immunoaffinity Beads Cat#: 8876
Curated Info

72

Zhou J (2012) CST Curation Set: 13841; Year: 2012; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine (P-Tyr-1000) Rabbit mAb Cat#: 8954, Phospho-Tyrosine Rabbit mAb (p-Tyr-1000) Immunoaffinity Beads Cat#: 8876
Curated Info

73

Tucker M (2012) CST Curation Set: 13493; Year: 2012; Biosample/Treatment: cell line, 23132/87[RAIG1(knockdown)]/GPRC5A knockdown; Disease: gastric cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

74

Tucker M (2012) CST Curation Set: 13494; Year: 2012; Biosample/Treatment: cell line, 23132/87/untreated; Disease: gastric cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

75

Lakshmanan I, et al. (2012) MUC16 induced rapid G2/M transition via interactions with JAK2 for increased proliferation and anti-apoptosis in breast cancer cells. Oncogene 31, 805-17
21785467   Curated Info

76

Mulhern D (2012) CST Curation Set: 13107; Year: 2012; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

77

Mulhern D (2012) CST Curation Set: 13108; Year: 2012; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

78

Mulhern D (2012) CST Curation Set: 13112; Year: 2012; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

79

Rikova K (2012) CST Curation Set: 13730; Year: 2012; Biosample/Treatment: cell line, Mix of TMT treated cell lines 2/treated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine (P-Tyr-1000) Rabbit mAb Cat#: 8954, Phospho-Tyrosine Rabbit mAb (p-Tyr-1000) Immunoaffinity Beads Cat#: 8876
Curated Info

80

Rikova K (2012) CST Curation Set: 13731; Year: 2012; Biosample/Treatment: cell line, Mix of TMT treated cell lines 3/treated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine (P-Tyr-1000) Rabbit mAb Cat#: 8954, Phospho-Tyrosine Rabbit mAb (p-Tyr-1000) Immunoaffinity Beads Cat#: 8876
Curated Info

81

Rikova K (2012) CST Curation Set: 13729; Year: 2012; Biosample/Treatment: cell line, Mix of TMT treated cell lines 1/treated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine (P-Tyr-1000) Rabbit mAb Cat#: 8954, Phospho-Tyrosine Rabbit mAb (p-Tyr-1000) Immunoaffinity Beads Cat#: 8876
Curated Info

82

Possemato A (2012) CST Curation Set: 13553; Year: 2012; Biosample/Treatment: cell line, NCI-H1703/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

83

Possemato A (2012) CST Curation Set: 13559; Year: 2012; Biosample/Treatment: cell line, mixTMT(A549,H3255,MKN45,H3122,,H1703,H1650)/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

84

Tucker M (2012) CST Curation Set: 13496; Year: 2012; Biosample/Treatment: cell line, Colo-680N[RAIG1(knockdown)]/GPRC5A knockdown; Disease: esophageal cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

85

Tucker M (2012) CST Curation Set: 13497; Year: 2012; Biosample/Treatment: cell line, Colo-680N/untreated; Disease: esophageal cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

86

Zhou J (2012) CST Curation Set: 12609; Year: 2012; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY
Curated Info

87

Zhou J (2012) CST Curation Set: 12610; Year: 2012; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY
Curated Info

88

Zhou J (2012) CST Curation Set: 12612; Year: 2012; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY
Curated Info

89

Mulhern D (2012) CST Curation Set: 13337; Year: 2012; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine (P-Tyr-1000) Rabbit mAb Cat#: 8954, Phospho-Tyrosine Rabbit mAb (p-Tyr-1000) Immunoaffinity Beads Cat#: 8876
Curated Info

90

Mulhern D (2012) CST Curation Set: 13338; Year: 2012; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

91

Mulhern D (2012) CST Curation Set: 13339; Year: 2012; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

92

Mulhern D (2012) CST Curation Set: 13340; Year: 2012; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

93

Mulhern D (2012) CST Curation Set: 13335; Year: 2012; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY
Curated Info

94

Mulhern D (2012) CST Curation Set: 13336; Year: 2012; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY
Curated Info

95

Rikova K (2012) CST Curation Set: 13324; Year: 2012; Biosample/Treatment: cell line, A549/untreated; Disease: lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

96

Mulhern D (2012) CST Curation Set: 13331; Year: 2012; Biosample/Treatment: cell line, HCT 116/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY
Curated Info

97

Mulhern D (2012) CST Curation Set: 13332; Year: 2012; Biosample/Treatment: cell line, HCT 116/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY
Curated Info

98

Mulhern D (2012) CST Curation Set: 13333; Year: 2012; Biosample/Treatment: cell line, HCT116/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine (P-Tyr-1000) Rabbit mAb Cat#: 8954, Phospho-Tyrosine Rabbit mAb (p-Tyr-1000) Immunoaffinity Beads Cat#: 8876
Curated Info

99

Mulhern D (2011) CST Curation Set: 13266; Year: 2011; Biosample/Treatment: cell line, K-562/untreated &'||' untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

100

Mulhern D (2011) CST Curation Set: 13267; Year: 2011; Biosample/Treatment: cell line, K-562/untreated &'||' untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

101

Mulhern D (2011) CST Curation Set: 13268; Year: 2011; Biosample/Treatment: cell line, K-562/untreated &'||' untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

102

Mulhern D (2011) CST Curation Set: 13106; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

103

Mulhern D (2011) CST Curation Set: 13111; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

104

Tsai YM, et al. (2011) Glabridin inhibits migration, invasion, and angiogenesis of human non-small cell lung cancer A549 cells by inhibiting the FAK/rho signaling pathway. Integr Cancer Ther 10, 341-9
21059620   Curated Info

105

Mulhern D (2011) CST Curation Set: 12687; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

106

Mulhern D (2011) CST Curation Set: 12689; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

107

Mulhern D (2011) CST Curation Set: 12691; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

108

Mulhern D (2011) CST Curation Set: 12695; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

109

Mulhern D (2011) CST Curation Set: 12697; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

110

Mulhern D (2011) CST Curation Set: 13031; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY
Curated Info

111

Mulhern D (2011) CST Curation Set: 13033; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY
Curated Info

112

Grebien F, et al. (2011) Targeting the SH2-kinase interface in Bcr-Abl inhibits leukemogenesis. Cell 147, 306-19
22000011   Curated Info

113

Miotto B, Struhl K (2011) JNK1 phosphorylation of Cdt1 inhibits recruitment of HBO1 histone acetylase and blocks replication licensing in response to stress. Mol Cell 44, 62-71
21856198   Curated Info

114

Mulhern D (2011) CST Curation Set: 12641; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

115

Mulhern D (2011) CST Curation Set: 12642; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

116

Mulhern D (2011) CST Curation Set: 12643; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

117

Mulhern D (2011) CST Curation Set: 12644; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

118

Mulhern D (2011) CST Curation Set: 12578; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

119

Mulhern D (2011) CST Curation Set: 12579; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

120

Mulhern D (2011) CST Curation Set: 12580; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

121

Mulhern D (2011) CST Curation Set: 12581; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

122

Mulhern D (2011) CST Curation Set: 12582; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

123

Moritz A (2011) CST Curation Set: 12517; Year: 2011; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

124

Moritz A (2011) CST Curation Set: 12518; Year: 2011; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

125

Moritz A (2011) CST Curation Set: 12519; Year: 2011; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

126

Mulhern D (2011) CST Curation Set: 12552; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

127

Li C, et al. (2011) Oncogenic role of EAPII in lung cancer development and its activation of the MAPK-ERK pathway. Oncogene 30, 3802-12
21478903   Curated Info

128

Deng L, et al. (2011) Hepatitis C virus infection promotes hepatic gluconeogenesis through an NS5A-mediated, FoxO1-dependent pathway. J Virol 85, 8556-68
21697492   Curated Info

129

Mulhern D (2011) CST Curation Set: 12471; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY
Curated Info

130

Mulhern D (2011) CST Curation Set: 12472; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY
Curated Info

131

Mulhern D (2011) CST Curation Set: 12473; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY
Curated Info

132

Mulhern D (2011) CST Curation Set: 12474; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY
Curated Info

133

Mulhern D (2011) CST Curation Set: 12475; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

134

Zhou J (2011) CST Curation Set: 12495; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

135

Zhou J (2011) CST Curation Set: 12497; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

136

Zhou J (2011) CST Curation Set: 12341; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

137

Zhou J (2011) CST Curation Set: 12342; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

138

Zhou J (2011) CST Curation Set: 12343; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

139

Zhou J (2011) CST Curation Set: 12344; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

140

Zhou J (2011) CST Curation Set: 12345; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

141

Zhou J (2011) CST Curation Set: 12346; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

142

Zhou J (2011) CST Curation Set: 12347; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

143

Zhou J (2011) CST Curation Set: 12348; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

144

Mulhern D (2011) CST Curation Set: 12399; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

145

Mulhern D (2011) CST Curation Set: 12400; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

146

Mulhern D (2011) CST Curation Set: 12401; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

147

Mulhern D (2011) CST Curation Set: 12402; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

148

Mulhern D (2011) CST Curation Set: 12428; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

149

Mulhern D (2011) CST Curation Set: 12429; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

150

Mulhern D (2011) CST Curation Set: 12430; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

151

Mulhern D (2011) CST Curation Set: 12431; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

152

Mulhern D (2011) CST Curation Set: 12432; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

153

Mulhern D (2011) CST Curation Set: 12439; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

154

Mulhern D (2011) CST Curation Set: 12440; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

155

Mulhern D (2011) CST Curation Set: 12443; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

156

Guo A (2011) CST Curation Set: 12074; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y/M)Xp[ST](L/I/M)
Curated Info

157

Zhou J (2011) CST Curation Set: 12314; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

158

Zhou J (2011) CST Curation Set: 12316; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

159

Zhou J (2011) CST Curation Set: 12317; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY
Curated Info

160

Zhou J (2011) CST Curation Set: 12318; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY
Curated Info

161

Zhou J (2011) CST Curation Set: 12319; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY
Curated Info

162

Zhou J (2011) CST Curation Set: 12320; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

163

Guo A (2011) CST Curation Set: 12174; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

164

Zhou J (2011) CST Curation Set: 12026; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY(YXXM) Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Tyr) p85 PI3K Binding Motif Antibody Cat#: 3821
Curated Info

165

Zhou J (2011) CST Curation Set: 12029; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY(YXXM) Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Tyr) p85 PI3K Binding Motif Antibody Cat#: 3821
Curated Info

166

Zhou J (2011) CST Curation Set: 12030; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY(YXXM) Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Tyr) p85 PI3K Binding Motif Antibody Cat#: 3821
Curated Info

167

Zhou J (2011) CST Curation Set: 12031; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY(YXXM) Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Tyr) p85 PI3K Binding Motif Antibody Cat#: 3821
Curated Info

168

Zhou J (2011) CST Curation Set: 12032; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY(YXXM) Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Tyr) p85 PI3K Binding Motif Antibody Cat#: 3821
Curated Info

169

Zhou J (2011) CST Curation Set: 12033; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY(YXXM) Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Tyr) p85 PI3K Binding Motif Antibody Cat#: 3821
Curated Info

170

Moritz A (2011) CST Curation Set: 12370; Year: 2011; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

171

Kim HD, Kim TS, Kim J (2011) Aberrant ribosome biogenesis activates c-Myc and ASK1 pathways resulting in p53-dependent G1 arrest. Oncogene 30, 3317-27
21383696   Curated Info

172

Guo A (2011) CST Curation Set: 12017; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

173

Guo A (2011) CST Curation Set: 12018; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

174

Guo A (2011) CST Curation Set: 12024; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

175

Sarkar S, et al. (2011) Complex inhibitory effects of nitric oxide on autophagy. Mol Cell 43, 19-32
21726807   Curated Info

176

Organ SL, et al. (2011) Quantitative Phospho-Proteomic Profiling of Hepatocyte Growth Factor (HGF)-MET Signaling in Colorectal Cancer. J Proteome Res 10, 3200-11
21609022   Curated Info

177

Wang J, Zhou JY, Wu GS (2011) Bim protein degradation contributes to cisplatin resistance. J Biol Chem 286, 22384-92
21561860   Curated Info

178

Hrdinka M, et al. (2011) PRR7 is a transmembrane adaptor protein expressed in activated T cells involved in regulation of T cell receptor signaling and apoptosis. J Biol Chem 286, 19617-29
21460222   Curated Info

179

Possemato A (2011) CST Curation Set: 11906; Year: 2011; Biosample/Treatment: cell line, NCI-H1650/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

180

Possemato A (2011) CST Curation Set: 11915; Year: 2011; Biosample/Treatment: cell line, U118 MG/untreated; Disease: astrocytoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

181

Possemato A (2011) CST Curation Set: 11916; Year: 2011; Biosample/Treatment: cell line, U118 MG/untreated; Disease: astrocytoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

182

Possemato A (2011) CST Curation Set: 11917; Year: 2011; Biosample/Treatment: cell line, NCI-H1650/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

183

Possemato A (2011) CST Curation Set: 11918; Year: 2011; Biosample/Treatment: cell line, NCI-H1650/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

184

Possemato A (2011) CST Curation Set: 11919; Year: 2011; Biosample/Treatment: cell line, NCI-H3122/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

185

Possemato A (2011) CST Curation Set: 11921; Year: 2011; Biosample/Treatment: cell line, HCC78/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

186

Possemato A (2011) CST Curation Set: 11922; Year: 2011; Biosample/Treatment: cell line, HCC78/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

187

Possemato A (2011) CST Curation Set: 11923; Year: 2011; Biosample/Treatment: cell line, HCT116/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

188

Possemato A (2011) CST Curation Set: 11924; Year: 2011; Biosample/Treatment: cell line, HCT116/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

189

Possemato A (2011) CST Curation Set: 11927; Year: 2011; Biosample/Treatment: cell line, U118 MG/untreated; Disease: astrocytoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

190

Plaza-Menacho I, et al. (2011) Focal adhesion kinase (FAK) binds RET kinase via its FERM domain, priming a direct and reciprocal RET-FAK transactivation mechanism. J Biol Chem 286, 17292-302
21454698   Curated Info

191

Guo A (2011) CST Curation Set: 11646; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

192

Guo A (2011) CST Curation Set: 11647; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

193

Guo A (2011) CST Curation Set: 11648; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

194